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Bony content of oxalate in patients with primary hyperoxaluria or
oxalosis-unrelated renal failure. Oxalate retention occurs in end-stage
renal failure. Regular dialysis treatment does not prevent progressive
accumulation of oxalate in cases of ESRF due to primary hyperoxaluria
(PH), whereas such accumulation seldom seems to occur in oxalosis-
unrelated ESRF. To elucidate this issue we have measured the bony
content of oxalate on biopsies of the iliac crest taken from 32 uremic
patients, 7 of them with ESRF associated with PHi (6 cases) or PH2 (1
case). Ten subjects with normal renal function and no evidence of
metabolic bone disease were taken as controls. Only trace amounts levels
of oxalate were detected in normal subjects and oxalate to phosphate ratio
was below 3:10,000. Non-PH dialyzed patients exhibited fivefold increases
in oxalate levels, which rose to 5.1 3.6 smol/g bony tissue. Calcium
oxalate was estimated to represent 0.18% of the hydroxyapatite content of
bone. Oxalate amounts were neither related to pre-dialysis plasma levels
of oxalate, nor with duration of dialysis treatment, suggesting that
accumulation was not progressive disorder. Oxalate levels were slightly
higher in patients with a low turnover osteodystrophy compared to those
with a high turnover pattern. Dialyzed patients with PH had remarkable
increases in oxalate levels, which ranged between 14.8 and 907 J.Lmol/g
bony tissue. Oxalate deposition appeared to be progressive in that oxalate
levels were significantly related to time on dialysis. In three patients
calcium oxalate was a significant fraction of the mineralized bone. The
occurrence of calcium oxalate crystals affected the histomorphometric
patterns, that were featured by an increase in resorptive areas and a
decrease in bone formation rate. We suggest that oxalate measurement in
bony tissue gives reliable information of the status of oxalate burden in
dialyzed patients. In this study oxalate deposition in bone has emerged as
a non-progressive and meaningless event in patients with oxalosis-unre-
lated ESRF. Conversely, in patients with primary hyperoxaluria on
maintenance hemodialysis, it evolves following a pattern so relentless that
such patients should clearly be considered for organ transplantation as
soon as possible.
Because the kidney is virtually the only route by which oxalate
is eliminated from body fluids, oxalate balance depends on the
difference between de novo generation and urinary excretion.
End-stage renal failure (ESRF) causes oxalate retention [1, 21,
and dialysis treatment must substitute kidney function to maintain
oxalate balance [3, 4]. The results of some recent studies support
the contention that, unless increased oxalate generation occurs,
massive oxalate accumulation is not a common feature in patients
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on either hemodialysis or peritoneal dialysis for ESRF unrelated
to primary hyperoxaluria [4—6]. Conversely, relentlessly evolving
oxalate deposition invariably occurs in body tissues of patients
with ESRF associated with primary hyperoxaluria (PH) [7—9]. In
fact, whereas systemic oxalosis constitutes a life threatening event
in patients on regular dialysis treatment (RDT) for PH-related
ESRF [10, 11], detectable deposits of oxalate are only reported
anecdotically, and none in recently dialyzed patients with PH-
unrelated ESRF [12—14]. However, presence and extention of
oxalate deposits are difficult to detect, and only indirect proce-
dures have so far been pursued to elucidate this issue [4, 8, 9].
Controversy continues with some authors contending that sys-
temic oxalosis is inevitable in patients on maintenance hemodial-
ysis [12—14], whereas others deny it [4, 6, 15].
Due to a high calcium content, bone is a representative and
precocious site of oxalotic deposits in cases of chronic retention of
oxalate. On the other hand, bone biopsy is regularly carried out in
dialysis patients to be investigated for renal osteodystrophy [16].
The above reasons have prompted us to undertake a systematic
study aimed at assessing the oxalate content of specimens from
iliac crest biopsies, taken for bone histomorphometry.
Methods
Subjects studied
We enrolled a total of 42 subjects. Ten (4 males and 6 females,
aged 34.5 22.2 years) had no evidence of metabolic bone
disease and bone biopsy had been performed during surgery for
post-traumatic diseases. In one case the bone specimen was taken
at autopsy from a patient who died of cardiac failure. All of these
were taken as control subjects.
Twenty-five (6 males, 19 females, aged 48.0 15.8 years) were
patients on RDT for 94 62 months, for ESRF unrelated to
hyperoxaluria syndromes (non-PH). Seven patients had primary
hyperoxaluria type 1 (6 patients) or type 2 (1 patient), which had
been diagnosed by means of pertinent biochemical measurements
on serum, urine and/or dialysate. In five patients diagnosis of PHi
was confirmed by detection of reduced or absent alanine:glyoxy-
late aminotransferase (AGT) activity on liver biopsy [17]. Hepatic
AGT activity was normal in the patient with PH2 [18]. Six of the
patients with PH had been on renal replacement therapy (RRT)
for 34.7 25.8 months. Five of these were on RDT, whereas the
PH2 patient had been changed to chronic peritoneal dialysis
(CPD) after he had repeatedly thrombosed his arteriovenous
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fistulas. One PHi patient had renal insufficiency not yet requiring
RRT, her creatinine clearance being 24 ml/min/1.73 m2 b.s.a. at
the time she was studied. All the patients on RDT were on
standard dialysis schedules consisting of three- to four-hour
sessions three times weekly with 1.6 m2 AN69, polysulfone or
PMMA membrane filters. Occasionally, the weekly sessions in
PHi patients were increased to four or five for periods of a few
months. The PH2 patient was exchanging 8 liters daily, using a
standard solution (Dianeal) intraperitoneally. All the patients on
RDT were taking phosphate binders, such as calcium carbonate,
calcium acetate or magnesium hydroxide at usual dosages. None
of the non-PH patients was on pyridoxine supplementation,
whereas all the PHi, including the non-dialyzed one, were taking
pyridoxine 300 to 900 mg/daily.
Sampling and analytical procedures
All the bone samples to be analyzed were from percutaneous
biopsy taken at the iliac crest. A 10 to 80 mg specimen was
processed according to a procedure detailed elsewhere [19].
Briefly, the slice was carefully cleaned of any non-osseous mate-
rial, washed three times with distilled water to remove preserva-
tives and then added with 500 tl of working mixture, which was
prepared as follows: MPS buffer (50 mmol, E. Merck) and CaCl2
X 2H20 (5 mmol) in 100 ml distilled water were brought to pH
7.20 by adding sodium hydroxyde (4 mol) and then mixed with 10
ml (about 880 UI) of Ri Collagenase type IA Crude (Sigma
Chemical). The resulting solution was subdivided into twenty 0.5
ml aliquots and stored frozen at —20°C until used. After it had
been added to this working mixture the sample was left to stand
for 24 hours at 37°C and shaken every so often. The slice was then
rinsed three times with distilled water, dehydrated by mixing twice
with ethanol 100% and dried at 37°C for four hours. After being
weighed accurately the resulting fragment was put into a polyeth-
ylene vessel and covered with 50 to 200 pJ of concentrated
hydrochloric acid. The bone specimen was completely dissolved in
48 to 72 hours at room temperature. The resulting solution was
added with distilled water to a final volume of 2 to 7.5 ml (in
proportion to the amount of hydrochloric acid used), filtered
through a 0.22 tm Millipore filter and stored frozen at —20°C
until analysis.
Oxalate and phosphate were measured on the final solutions by
ion chromatography, using Dionex QIC apparatus equipped with
a conductimetric detector and a conductivity suppressor (AMMS/
II). AG-4A/AS-4A anion separators were used as the stationary
phase, eluent was a 1.4/1.8 mmol/liter sodium carbonate/bicarbon-
ate aqueous solution pumped at a flow rate of 2.0 mI/mm. Calcium
was determined by atomic absorption spectrometry. Oxalate,
calcium and phosphate were expressed as mol/g bony tissue.
Estimated amounts of calcium oxalate monohydrate (molecular
wt 146.12) and hydroxyapatite (molecular wt 1004.64) in the bone
specimen were also calculated and given as mg/g bony tissue.
To assess reproducibility of the oxalate assay, specimens from
twelve bone biopsies were analyzed in duplicate, seven of which
containing cortical and trabecular bone in different proportions.
The results, on two subsets of range 1.0 through 4.7 imol/g and
6.7 through 42 jrmol/g bony tissue, did not differ significantly and
gave imprecision standard deviations (SD [(1d2)/2n]½) of 0.4
and 0,9 jxmol/g, respectively. Recoveries of oxalate were mea-
sured on three samples from non-PH patients on RDT. The
hydrochloric acid extracts were subdivided into two aliquots, one
Table 1. Plasma levels of oxalate, glycolate and L-glycerate in
individual patients with PH as well as means from non-PH dialysis
patients and normal subjects
Patient
Oxalate Olycolate L-glycerate
uinol/1iter
G.V., PH2 170 28 512
S.G., PHi 198 167 nd
F.G., PHi 184 143 nd
DR., PHi 190 271 nd
D.M.P., PHi 124 267 nd
PG., PHi 116 525 nd
G.R., pp 38 310 nd
Non-PH 47.4 11.4 6.6 2.8 nd
Normal subjects 1.4 0.7 7.9 2.4 nd
Abbreviation nd is non-detectable.
aAdvanced renal failure not yet on RDT
of which was added with 20 nmoles of sodium oxalate: percent
recoveries were 91.7, 97.8 and 103.4, respectively.
To test whether acidic digestion accomplished complete disso-
lution of bone mineral the following procedure was carried out on
two samples. The mixture obtained after acidic digestion was
centrifuged at 10,000 x g for 30 minutes, the supernate was
separated and analyzed for oxalate, calcium and phosphate as
described above. The residue was rinsed twice with distilled water,
added with 200 1.d of concentrated nitric acid and let to stand at
100°C overnight. Both this solution and a nitric acid blank were
brought to 1 ml final volume with distilled water and analyzed for
calcium. Calcium content on these extracts was less than 1% that
measured on the supernates.
Bone histomorphometry was carried out by a previously de-
scribed technique [20].
Fasting or pre-dialysis blood samples were analyzed for oxalate,
glycolate and L-glycerate using methods described elsewhere
[21—23].
Results are means SD. Statistical treatment of the data has
been performed by means of a computer package (Statistix).
Results
Table 1 shows values of oxalate, glycolate and L-glycerate
plasma levels in individual patients with PH, and means from both
non-PH dialysis patients and control subjects. Plasma oxalate
levels in PH patients on RDT did not overlap at all with those
from other subjects under study. The value of 38 jrmol/liter was
found in the patient with advanced renal failure not yet on RDT.
Differentiation between PHi and PH2 was made by assessing
elevated glycolate levels in the former and elevated L-glycerate in
the latter.
Oxalate, phosphate and calcium content in the bone specimens
from the iliac crest in the different groups of patients are listed in
Table 2. The data from the PH patients are given separately.
Table 2 shows that oxalate levels are steeply elevated in dialyzed
PH patients: both absolute values and phosphate ratios were
fiftyfold and three-hundredfold higher than those of non-PH
patients on RDT and control subjects, respectively. The differ-
ences were of the same order of magnitude if the estimated
content of calcium oxalate monohydrate was considered (Table
3). Oxalate levels increased slightly in the non dialyzed patient
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Table 2. Oxalate, phosphate and calcium content in the bone specimens from the iliac crest biopsy
Patient
Oxalate Phosphate Calcium Ox/P Ca/P
uno1/g bony tissue pmol/mmol
G.V., P112 42 1860 3800 22.7 2.04
S.G., PHi 907 2080 4320 436 2.08
F.G., PHI 14.8 3100 5570 4.77 1.79
D.R., PHi 106 2490 4680 42.6 1.88
D.M.P., PHi 611 2750 5570 222 2.02
PG., PHi 493 2390 4280 20 1.79
mean SD 362 365k' 2445 448" 4703 727 156 167' 1.91 0.13
G.R., pd 4.2 3100 5280 1.4 1.7
Non-PH on RDT 5.1 3.6c 2702 613" 4540 822" 2.07 1.50' 1.68 0.19
Control subjects 0.8 0.2 3068 304 5027 476 0.28 0.09 1.64 0.13
Oxalate and calcium levels are also expressed as phosphate ratios.
a P < 0.001 vs. both non-PH on RDT and control subjects
hP < 0.05 vs. control subjects
P < 0.001 vs. both control subjects and PH on RDT
dAdvanced renal failure not yet on RDT
Table 3. Calcium oxalate monohydrate (CaOx) and hydroxyapatite
(1-lAP) contents in the bone samples considered
Patient
CaOx HAP
CaOx/HAP
%mg/g bony tissue
G.V., P112 6.14 310 2.0
S.G., PHi 132 348 37.9
F.G., PHi 2.17 521 0.4
D.R., PHI 15.5 417 3.7
D.M.P., PHi 89.0 461 19.5
PG., PHi 72.0 400 18.0
mean SD 52.8 53.Ia 410 76" 13.5 14.5
G.R., PH1d 0.62 523 0.12
Non-PH on 0.75 0.53' 453 104" 0.18 0.13c
RDT
Control subjects 0.12 0.03 514 52 0.024 0.01
ap < 0.001 vs. both non-PH on RDT and control subjects.
"P < 0.05 vs. normal subjects
P < 0.001 vs. both control subjects and PH on RDT
' Advanced renal failure not yet on RDT
with PHi, whose values were similar to those from oxalosis-
unrelated patients on RDT, but above the reference range for
normal subjects. Samples from both PH and non-PH dialyzed
patients had a slight but significant decrease in the hydroxyapatite
content compared to control subjects.
The amount of calcium oxalate in bone from dialyzed subjects
was significantly related to time on dialysis in PH patients (P =
0.0004), but not in those on RDT for oxalosis-unrelated renal
failure (Fig. 1). There was no relationship in either group between
bony oxalate and pre-dialysis plasma levels of oxalate.
The results of chemical studies of bone were also analyzed in
relation to the hystomorphometric data. Non-PH patients were
subdivided into two classes of uremic osteodystrophy, based on
the results of dynamic measurements carried out by the tetracy-
cline labeling technique: high turnover (pure or mixed osteitis
fibrosa) and low turnover (osteomalacia or adynamic) bone
disease. Table 4 shows that PH patient had a low turnover bone
disease characterized by a significant decrease in both mineral
apposition and bone formation rates. There was an increase in the
area of bone resorption, attributable to giant cell reaction sur-
rounding the calcium oxalate crystals. Some differences in mineral
content of bone were found in the two subgroups of non-PH
patients, both of which had lower values of bony hydroxyapatite as
compared to control subjects, but the significance level was only
reached by the low turnover subgroup (P < 0.005). For the latter
patients, only a slight increase in calcium oxalate content was
observed when compared to the high turnover subgroup.
Discussion
Oxalate retention invariably occurs in patients with ESRF.
While current dialysis schedules do not restore oxalate plasma
levels to normal, whether progressive oxalate accumulation occurs
is still controversial. Major problems concerning this issue depend
on the difficulty of assessing oxalate generation in a multicom-
partmental system where unpredictable amounts of oxalate are
possibly removed from an exchangeable pool and sequestered in
a hidden pool as insoluble calcium oxalate [7—9]. An essential
condition for this to occur is that body fluids, where crystallization
takes place, be supersaturated with calcium oxalate. In general,
this event happens when oxalate levels increase above the thresh-
old of saturation, which, in plasma ultrafiltrates and at normal
ionized calcium levels, corresponds to about 50 ixmol/liter [24, 25].
We have previously reported that most of the plasma ultrafil-
trates from patients on both hemodialysis and CPD for oxalosis-
unrelated ESRF are either undersaturated or only slightly super-
saturated with respect to calcium oxalate monohydrate [6, 25].
Kinetic studies have also demonstrated that oxalate generation is
matched by dialysis oxalate removal [4, 9]. Conversely, plasma
samples from dialyzed patients with primary or enteric hyperox-
aluria were more than threefold supersaturated [9, 25] and, from
balance studies, oxalate accumulation appeared to take place
starting a few hours after the end of a dialysis session [91.
In short, these results would suggest that massive oxalate
deposition should not be a feature of patients on RDT unless
renal failure is either caused by hyperoxaluric syndromes or
associated with oxalate generation disorders. However, all the
aforementioned experimental results provide only indirect docu-
mentation of oxalate balance in different dialysis settings. There-
fore, the present study was designed to test the above hypothesis
by directly measuring tissue accumulation of oxalate. Because
bone specimens are easily available from biopsies made for
histomorphometry, bone represented an ideal tissue for our
Table 4. Bony content of calcium oxalate and hydroxyapatite in
patients with primaiy hyperoxaluria and patients with oxalosis-unrelated
CFR subdivided into high turnover and low turnover osteodystrophy
N
PH
6
Non-PH
High
turnover
19
Low
turnover
6
Resorption surface
Mineral apposit.rate
Bone formation rate
Calcium Oxalate
Hydroxyapatite
14.0 7.2
0.7 0,5
0.07 0.07
45 52d
426 82
18.0 7.0
1.2 0.4
0.48 0.32c
0.55 0.27e
464 114
6.0 44a
0.8 0.16"
0.09 0.07
1.38 0.67
415 51
Definition of terms: Resorption surface is the percentage of the
resorption surface with respect to total bone surface. Mineral apposition
rate, as piday, is the average width of mineral deposited per day. Bone
formation rate, as 3//L2/day, is the volume of mineral deposited per tissue
area per day.
UP < 0.001 vs. PT-I and high turnover
'P < 0.005 vs. PH and high turnover
P < 0.001 vs. both PH and low turnover
"P < 0.001 vs. both high and low turnover
°P < 0.05 vs. low turnover
purposes. Moreover, due to a high calcium content it should be a
preferential site of calcium oxalate deposition. -
To the best of our knowledge oxalate has never been measured
on bony tissue, and therefore preliminary points to deal with were
a proper sampling and handling of specimens to be assayed. All
the analyzed samples were from biopsies at the iliac crest per-
formed with the same technique. Measurements made in dupli-
cate upon segments from the same biopsy showed a satisfactory
reproducibility of the results. An acceptable cleansing from
non-mineral material was obtained by incubating with a mixture
of collagenase and protease. Oxalate was virtually absent in
rinsing water used after incubation, suggesting that no significant
leak was caused by this procedure. Acidic digestion yielded a
virtually complete dissolution of bone mineral, and recoveries of
added oxalate were always higher than 90%. Because all the data
must refer to units of bony weight, another potential source of
error could be inaccuracy in weighing the specimens. To obviate
this we chose to express oxalate (and calcium) results as phos-
2.5
2-
E 1.50I
x0
cc0
phate ratios as well. The reliability of our analytical procedure was
confirmed by the mean calcium-to-phosphate ratios we found in
normal subjects and non-oxalotic dialyzed patients, which were
near the ideal stoichiometric ratio expected in mature bone [26].
Mean calcium and phosphate contents per gram of bone also
depend on different processing of the specimens, being propor-
tionally higher if complete dehydration has been preliminarly
carried out, since 20% of wet bone is made up of water [27].
Because heat dehydration of the samples was not included in our
procedure, we assumed as reference values the results obtained
on bone specimens from ten normal subjects. The calculation of
the calcium oxalate monohydrate and hydroxyapatite contents
from the measured oxalate and phosphate assumes that these
anions are fully represented by these crystalline forms. This
simplified approach does not take into account that other calcium
oxalates and calcium phosphates compounds are possibly repre-
sented in bone. However, this should not be a source of inaccuracy
in the evaluation of differences among groups.
As expected, bone specimens from these normal subjects only
contained trace amounts of oxalate, ranging between 0.54 and
1.15 jimol/g bony tissue, with an oxalate-to-phosphate ratio in the
order of 0.28:1000 and an estimated content of calcium oxalate of
0.1 mglg bony tissue. Notably, oxalate concentration in serum
from normal individuals is 1 to 2 mol/liter, with an oxalate-to-
phosphate ratio of 1:1000 [21].
Conversely, specimens from patients with PH exhibited remark-
able amounts of oxalate. The dialyzed PH patients had as much as
14,8 to 907 .rmol oxalate per g bony tissue, and an oxalate-to-
phosphate ratio ranging between 5:1000 and 436:1000. Oxalate
was substituted for phosphate as calcium ligand in significant
proportion, so that the content of phosphate was lower than that
of controls. Calcium oxalate was a substantial fraction of the
mineral content of bone and in three patients it rose to 18%, 19%
and 38% of the hydroxyapatite content, thereby reducing the
amount of hydroxyapatite per gram of tissue. Oxalate accumula-
tion tended to be greater in patients on RDT for longer, suggest-
ing that oxalosis is a progressive event if such patients are
maintained on RDT. This was definitely demonstrated by
Mathews et al, who reported the progression of oxalate deposits
on serial biopsies: in one case quantitative histological techniques
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Fig. 1. Correlation between time on dialysis treatment and calcium oxalate content in bone from 6 patients with primaty hyperoxaluria (A) and 25 with
non-oxalotic end-stage renal failure (B).
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confirmed an increase in area occupied by oxalate from 2.3% at 11
months to 38.6% at 63 months [28].
These results are consistent with the view that current dialysis
schedules are inadequate to control the burden of body oxalate [8,
9]. Indeed, two PH patients who were being dialyzed with an urea
Kt/V of 1.3 were shown to remove less than 30% of the newly
generated oxalate, with an estimated accumulation of about 2 to
4 mmol/day [9]. Hystomorphometry indicated that deposition of
calcium oxalate crystals produced well defined changes in bone
turnover, that assumed a low turnover pattern when an increase in
resorption surfaces was observed. These peculiar features are
thought to be caused by a granulomatous reaction exerted by giant
cells around oxalate crystals [29] that is uncoupled with and
depresses the bone formation rate. Therefore, oxalosis-related
bone changes are quite different from those associated with
secondary hyperparathyroidism [30].
The bone specimen from the non-dialyzed PHi patient did not
contain notable accumulation of oxalate, and calcium oxalate
crystals were not seen on histology. This patient had been studied
when her residual renal function was about 20% of normal, with
plasma levels of oxalate still below the threshold of saturation with
calcium oxalate. These findings are consistent with previous
studies in which a significant oxalate accumulation is predicted to
start at GFRs ranging between 24 and 34 ml/min/1.73 m2 [31, 32].
Oxalate content in bone from oxalosis-unrelated dialyzed pa-
tients was by far lower than that of PH patients. There was no
overlap with the latter, except for results from the non-dialyzed
PH patient. In any case, oxalate and oxalate-to-phosphate ratio
were six- to ninefold higher on average than those of normal
subjects, but calcium oxalate was only a negligible component of
the mineralized bone. From our results this modest accumulation
of oxalate did not appear to be progressive, as it was unrelated to
duration of RDT. Prevailing pre-dialysis plasma levels of oxalate
were also unrelated to oxalate in bone. It is worth considering that
the differences in plasma oxalate levels between normal subjects
and patients on RDT are much more pronounced than the
differences in bony oxalate.
The mineral content measured on bone specimens reflected the
patterns emerging from the dynamic hystomorphometric data.
There was a significant decrease in the hydroxyapatite content as
compared to controls (P < 0.005) in patients with low turnover
osteodystrophy, but not in those with the high turnover type (P =
0.202). Correspondingly, calcium oxalate was slightly higher in low
turnover than in high turnover osteodystrophy (P = 0.027). The
two subgroups did not differ for age, sex, time on dialysis, or
pre-dialysis plasma levels of oxalate. Therefore, conclusions con-
cerning the possible clinical significance of these differences
cannot be drawn from the available data.
In conclusion, measurements of bony content of oxalate repre-
sent a suitable and reliable means to detect extrarenal deposition
of calcium oxalate. The results of the present study is consistent
with the view that systemic oxalosis is a relentlessly evolving
disorder in patients with ESRF associated with PH when main-
tained on hemodialysis. Conversely, oxalate accumulation appears
to be negligible, non-progressive and, from the clinical standpoint,
meaningless in dialysis patients with ESRF unrelated to primary
hyperoxaluria. Therefore, patients with ESRF caused by PH
should be considered as soon as possible for organ transplantation
[33]. Our procedure helps to quantify the burden of body oxalate
and the results may be used as a guideline for the timing and
choice of transplantation strategies. These patients with the
finding of oxalate stores should be strong candidates for combined
liver and kidney transplantation.
Reprint requests to Martino Marangella, MD., Laboratorio Calcolosi
Renale, Ospedale Mauriziano Umberto I, Largo Turati, 62. 10128 Torino,
Italy.
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